Asset Details
Do you wish to reserve the book?
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
Do you wish to request the book?
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011
Overview
A patient with refractory CLL had delayed development of the rapid tumor lysis syndrome and remission after an infusion of T cells engineered to express an antigen receptor capable of recognizing B cells (CD19) coupled to two signaling molecules.
With the use of gene-transfer techniques, T cells can be genetically modified to stably express antibodies on their surface, conferring new antigen specificity. Chimeric antigen receptors combine an antigen-recognition domain of a specific antibody with an intracellular domain of the CD3-zeta chain or FcγRI protein into a single chimeric protein.
1
,
2
Although chimeric antigen receptors can trigger T-cell activation in a manner similar to that of endogenous T-cell receptors, a major impediment to the clinical application of this technique to date has been limited in vivo expansion of chimeric antigen receptor T cells and disappointing clinical activity.
3
,
4
Chimeric antigen . . .
Publisher
Massachusetts Medical Society
Subject
/ Antigens
/ Biological and medical sciences
/ Chimera
/ Chronic lymphocytic leukemia
/ Hematologic and hematopoietic diseases
/ Humans
/ Immunotherapy - adverse effects
/ Leukemia
/ Leukemia, Lymphoid - immunology
/ Leukemia, Lymphoid - pathology
/ Leukemia, Lymphoid - therapy
/ Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
/ Lysis
/ Male
/ Receptors, Antigen, T-Cell - genetics
/ Tumor Lysis Syndrome - etiology
/ Tumors
